EKF Diagnostics Holdings plc
("EKF" or the "Company")
Update to distribution timetable
Following the release of the Company's announcement on 22 October 2018, the Company provides the below update in relation to its planned distribution timetable.
The updated anticipated timetable for the distribution is set out below:
|
|
2018 |
|
|
Record date for the Distribution |
Close of business on 23 October |
|
|
EKF ordinary shares marked as ex rights |
8.00am on 24 October |
|
|
Distribution declared by the board of directors |
24 October |
|
|
Admission of issued and to be issued RENX Shares to trading on AIM |
2 November |
|
|
|
|
|
|
|
2019 |
|
|
End of Lock-up Period |
22 April |
|
EKF shareholders on the register at close of business on 23 October 2018 ("Relevant EKF Shareholders") will receive one RENX Share for every 21.825 EKF ordinary shares held.
All times and dates in this announcement may be subject to change.
Enquiries:
|
EKF Diagnostics Holdings plc |
|
||
|
Christopher Mills, Non-Executive Chairman |
Tel: 029 2071 0570 |
||
|
Julian Baines, CEO
|
|
||
|
N+1 Singer (Nominated Adviser & Broker) |
Tel: 020 7496 3000 |
||
|
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)
|
|
||
|
Walbrook PR Limited |
Tel: 020 7933 8780 or ekf@walbrookpr.com |
||
|
Paul McManus / Lianne Cawthorne |
Mob: 07980 541 893 / 07584 391 303 |
||
|
|
|
|
|
About EKF Diagnostics Holdings plc www.ekfdiagnostics.com
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.